Fractyl Health (GUTS) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Fractyl Health (GUTS) over the past year, losing 24.6% versus a loss of 74.8%. MiNK Therapeutics is the larger company by market cap ($56.1 million vs $56.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | INKT |
|---|---|---|
| Share price | $4.23 | $11.00 |
| Market cap | $56.11M | $56.13M |
| 1-day change | -6.42% | -3.68% |
| YTD return | -83.98% | -1.35% |
| 1-year return | -74.82% | -24.61% |
| 5-year return | — | -90.83% |
| EPS (TTM) | $-10.56 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.34 | $16.93 |
| 52-week low | $4.14 | $8.48 |
| Distance from 52-week high | -85.58% | -35.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1327.90% | +254.55% |
| Average volume | 152.04K | 13.80K |
| Shares outstanding | 13.26M | 5.10M |
| Employees | 100 | 15 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed GUTS by 50.2 percentage points over the past year.
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
GUTS vs INKT FAQ
Which is bigger, Fractyl Health or MiNK Therapeutics?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $56.13M compared with $56.11M for Fractyl Health (GUTS).
Which stock has performed better over the past year, GUTS or INKT?
INKT returned -24.61% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and MiNK Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Fractyl Health and Biotechnology: Biological Products (No Diagnostic Substances) for MiNK Therapeutics.